M T Ziolo1, H Katoh, D M Bers. 1. Department of Physiology, Loyola University Medical Center, Maywood, IL 60153, USA.
Abstract
BACKGROUND: beta-adrenergic hyporesponsiveness in many cardiomyopathies is linked to expression of inducible nitric oxide synthase (iNOS) and increased production of NO. The purpose of this study was to examine whether iNOS expression alters the function of the sarcoplasmic reticulum (SR) Ca(2+) release channel (ryanodine receptor, RyR) during beta-adrenergic stimulation. METHODS AND RESULTS: Expression of iNOS was induced by lipopolysaccharide (LPS) injection (10 mg/kg) 6 hours before rat myocyte isolation. Confocal microscopy (fluo-3) was used to measure Ca(2+) spark frequency (CaSpF, reflecting resting RyR openings) and Ca(2+) transients. CaSpF was greatly increased by the adenylate cyclase activator forskolin (100 nmol/L) in normal myocytes (iNOS not expressed), but this effect was suppressed (by 77%) in LPS myocytes (iNOS expressed). When NO production by iNOS was inhibited by aminoguanidine (1 mmol/L), there was a further increase in the forskolin-induced CaSpF in LPS myocytes (to levels similar to the forskolin-stimulated CaSpF in normal myocytes). This effect was also seen in myocytes isolated from a failing human heart. There was no effect of aminoguanidine on forskolin-stimulated CaSpF in normal myocytes. ODQ (10 micromol/L), an inhibitor of NO stimulation of guanylate cyclase, did not restore the forskolin-induced rise in CaSpF in LPS myocytes. Aminoguanidine also increased twitch Ca(2+) transient amplitude in LPS myocytes after forskolin application (independent of changes in SR Ca(2+) load). CONCLUSIONS: iNOS/NO depresses beta-adrenergic-stimulated RyR function through a cGMP-independent pathway (eg, NO- and/or peroxynitrite-dependent redox modification). This mechanism limits beta-adrenergic responsiveness and may be an important signaling pathway in cardiomyopathies, including human heart failure.
BACKGROUND: beta-adrenergic hyporesponsiveness in many cardiomyopathies is linked to expression of inducible nitric oxide synthase (iNOS) and increased production of NO. The purpose of this study was to examine whether iNOS expression alters the function of the sarcoplasmic reticulum (SR) Ca(2+) release channel (ryanodine receptor, RyR) during beta-adrenergic stimulation. METHODS AND RESULTS: Expression of iNOS was induced by lipopolysaccharide (LPS) injection (10 mg/kg) 6 hours before rat myocyte isolation. Confocal microscopy (fluo-3) was used to measure Ca(2+) spark frequency (CaSpF, reflecting resting RyR openings) and Ca(2+) transients. CaSpF was greatly increased by the adenylate cyclase activator forskolin (100 nmol/L) in normal myocytes (iNOS not expressed), but this effect was suppressed (by 77%) in LPS myocytes (iNOS expressed). When NO production by iNOS was inhibited by aminoguanidine (1 mmol/L), there was a further increase in the forskolin-induced CaSpF in LPS myocytes (to levels similar to the forskolin-stimulated CaSpF in normal myocytes). This effect was also seen in myocytes isolated from a failing human heart. There was no effect of aminoguanidine on forskolin-stimulated CaSpF in normal myocytes. ODQ (10 micromol/L), an inhibitor of NO stimulation of guanylate cyclase, did not restore the forskolin-induced rise in CaSpF in LPS myocytes. Aminoguanidine also increased twitch Ca(2+) transient amplitude in LPS myocytes after forskolin application (independent of changes in SR Ca(2+) load). CONCLUSIONS:iNOS/NO depresses beta-adrenergic-stimulated RyR function through a cGMP-independent pathway (eg, NO- and/or peroxynitrite-dependent redox modification). This mechanism limits beta-adrenergic responsiveness and may be an important signaling pathway in cardiomyopathies, including humanheart failure.
Authors: Mark J Kohr; Honglan Wang; Debra G Wheeler; Murugesan Velayutham; Jay L Zweier; Mark T Ziolo Journal: Free Radic Biol Med Date: 2008-04-04 Impact factor: 7.376
Authors: Jesper van der Pals; Michael I Götberg; Matthias Götberg; Lillemor Mattsson Hultén; Mia Magnusson; Sverker Jern; David Erlinge Journal: J Thromb Thrombolysis Date: 2011-07 Impact factor: 2.300
Authors: Mark T Ziolo; Susanne J Lewandowski; Jacquelyn M Smith; Fred D Romano; Gordon M Wahler Journal: Br J Pharmacol Date: 2003-03 Impact factor: 8.739
Authors: Jochen Steppan; Sungwoo Ryoo; Karl H Schuleri; Chris Gregg; Rani K Hasan; A Ron White; Lukasz J Bugaj; Mehnaz Khan; Lakshmi Santhanam; Daniel Nyhan; Artin A Shoukas; Joshua M Hare; Dan E Berkowitz Journal: Proc Natl Acad Sci U S A Date: 2006-03-13 Impact factor: 11.205
Authors: Mark J Kohr; Honglan Wang; Debra G Wheeler; Murugesan Velayutham; Jay L Zweier; Mark T Ziolo Journal: Cardiovasc Res Date: 2007-09-19 Impact factor: 10.787